Lexicon Pharmaceuticals, Inc. (LXRX)

Lexicon Pharmaceuticals Stock Forecast

LXRX's stock price has decreased by -69.91% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 3 analysts with 12-month price forecasts for Lexicon Pharmaceuticals stock have an average target of 3.67, with a low estimate of 1.00 and a high estimate of 6.00. The average target predicts an increase of 619.47% from the current stock price of 0.51.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$1.00	$3.67	$4.00	$6.00
Change	+96.04%	+619.47%	+684.16%	+1076.2%

Analyst Ratings

The average analyst rating for Lexicon Pharmaceuticals stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25	Apr '25
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	1	1
Hold	1	1	1	1	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Joseph Pantginis HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $4	Strong Buy	Reiterates	$4	+684.16%	Mar 28, 2025
Yasmeen Rahimi Piper Sandler	Piper Sandler	Buy Maintains $10 → $6	Buy	Maintains	$10 → $6	+1,076.24%	Mar 7, 2025
Joseph Stringer Needham	Needham	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Mar 7, 2025
Joseph Pantginis HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $4	Strong Buy	Reiterates	$4	+684.16%	Mar 7, 2025
Roanna Ruiz Leerink Partners	Leerink Partners	Buy → Hold Downgrades $1	Buy → Hold	Downgrades	$1	+96.04%	Mar 4, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

9.53M

Decreased by -69.35%

from 31.08M

Revenue Next Year

15.56M

Increased by 63.36%

from 9.53M

EPS This Year

-0.39

from -0.63

EPS Next Year

-0.34

from -0.39

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	24.00M	298.00K	139.00K	1.20M	31.08M	9.53M	15.56M	38.47M
Revenue Growth	-92.55%	-98.76%	-53.36%	766.19%	2,481.48%	-69.35%	63.36%	147.18%
EPS	-0.53	-0.60	-0.62	-0.80	-0.63	-0.39	-0.34	-0.30
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	8	8	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	23.2M	38.2M	86.2M
Avg	9.5M	15.6M	38.5M
Low	n/a	3.0M	1.7M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	-25.3%	301.2%	453.9%
Avg	-69.3%	63.4%	147.2%
Low	-	-68.1%	-89.3%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-0.37	-0.21	-0.11
Avg	-0.39	-0.34	-0.30
Low	-0.39	-0.46	-0.57

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.